Usted buscó: chemo (Inglés - Maltés)

chemo- therapy
kimoterapija

chemo only (n=116)
kimo waħdu (n=116)

chemo + herceptin (n=115)
kimo + herceptin (n=115)

or end of your chemo therapy.
du tirrispondi u jista ’ jbiddillek id- doża skond il- bżonn.

this type of medicine is called “chemo-therapy”.
din it-tip ta’ mediċina hi msejħa “kimoterapija”.

the use of cetuximab in combination with chemo-radiotherapy has so far not been adequately investigated.
l-użu ta’ cetuximab flimkien mal-kemo-radjuterapija s’issa ma kinitx investigata b’mod adegwat.

egfr mutation testing should be performed prior to initiation of tarceva therapy in chemo-naïve patients with advanced or metastatic nsclc.
ittestjar għall-mutazzjoni ta’ egfr għandu jsir qabel il-bidu ta’ terapija b’tarceva f’pazjenti b’nsclc avanzat jew metastatiku li qatt ma ħadu kimoterapija qabel.

chemo-physical risks arising from the use of powders, especially when those powders contain nano-particles;
riskji kimofiżiċi li jinħolqu mill-użu ta’ trabijiet, speċjalment meta dawn it-trabijiet fihom in-nanopartiċelli;

imbruvica is used on its own in adults who have received previous treatment for their disease, or in previously untreated patients for whom treatment with chemo-immunotherapy is not suitable.
imbruvica jintuża f'adulti li jkunu ħadu kura preċedenti għall-marda tagħhom, jew f'pazjenti li ma jkunux ħadu kura preċedenti li għalihom il-kura bil-kimoimmunoterapija mhix adatta.

patients between 65 and 70 years of age were required to have at least one comorbidity that precluded the use of frontline chemo-immunotherapy with fludarabine, cyclophosphamide, and rituximab.
pazjenti li kellhom bejn 65 u 70 sena kien jeħtieġ li jkollhom mill-inqas komorbidità waħda li tipprekludi l-użu tal-aktar kimoimmunoterapija importanti bi fludarabine, cyclophosphamide, u rituximab.

11 the nile delta, which constitute a uniqueecosystem based on chemo-synthesis;andthe eratosthenes seamount located to thesouth of cyprus, which hosts a number ofrare types of coral.
għaldaqstant l-stecf għandu rwol ewlieni biex jgħin lillkummissjoni tifformula linji politiċi li jvarjaw minn pjanijiet fittul għal għeluq ta’ emerġenza, billi

a patient-level data analysis has also been performed on more than 13 900 cancer patients (chemo-, radio-, chemoradio-, or no therapy) participating in 53 controlled clinical trials involving several epoetins.
analiżi tat-tagħrif fuq livell ta’ pazjenti sar ukoll fuq aktar minn 13 900 pazjent bil-kanċer (kimo-, radju-, kimoradju-, jew l-ebda terapija) li kienu qed jipparteċipaw f’53 prova klinika b’kontrolli, li kienu jinvolvu diversi epoetini.